Extended Data Fig. 3: Serological neutralizing activity against SHIV-AD8EO in macaques in Groups 1–3.
From: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life
Sera from the macaques in Group 1 (a-c), Group 2 (d-f), and Group 3 (g,h) were tested for their ability to neutralize the in vitro infectivity of SHIV-AD8EO in TZM-bl cells. Neutralizing titers [i.e., inhibitory dilutions at which 50% of neutralization (ID50) was observed] were derived from these assays and plotted against the right y-axis of each panel. As a reference, the serum concentrations of rh-eCD4-IgG2-LS (a-f) or rh-3BNC117-IgG1-LS (g,h) were plotted against the left y-axis. Sera from the Group 3 macaque rh3-3 were not assayed for anti-SHIV-AD8EO neutralizing antibodies because this animal was euthanized before the start of the oral SHIV challenge phase (gray shaded boxes).
